The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
Open accessAbstract
Introduction: MicroRNAs (miRNAs) are a group of small noncoding RNAs involved in the regulation of gene expression. As such, they regulate a large number of cellular pathways, and deregulation or altered expression of miRNAs is associated with tumorigenesis. In the current study, we evaluated the feasibility and clinical utility of circulating miRNAs as biomarkers for the detection and staging of breast cancer. Methods: miRNAs were extracted from a set of 84 tissue samples from patients with breast cancer and eight normal tissue samples obtained after breast-reductive surgery. After reverse transcription and preamplification, 768 miRNAs were profiled by using the TaqMan low-density arrays. After data normalization, unsupervised hierarchical cluster analysis (UHCA) was used to investigate global differences in miRNA expression between cancerous and normal samples. With fold-change analysis, the most discriminating miRNAs between both tissue types were selected, and their expression was analyzed on serum samples from 20 healthy volunteers and 75 patients with breast cancer, including 16 patients with untreated metastatic breast cancer. miRNAs were extracted from 200 μl of serum, reverse transcribed, and analyzed in duplicate by using polymerase chain reaction (qRT-PCR). Results: UHCA showed major differences in miRNA expression between tissue samples from patients with breast cancer and tissue samples from breast-reductive surgery (P < 0.0001). Generally, miRNA expression in cancerous samples tends to be repressed when compared with miRNA expression in healthy controls (P = 0.0685). The four most discriminating miRNAs by fold-change (miR-215, miR-299-5p, miR-411, and miR-452) were selected for further analysis on serum samples. All miRNAs at least tended to be differentially expressed between serum samples from patients with cancer and serum samples from healthy controls (miR-215, P = 0.094; miR-299-5P, P = 0.019; miR-411, P = 0.002; and miR-452, P = 0.092). For all these miRNAs, except for miR-452, the greatest difference in expression was observed between serum samples from healthy volunteers and serum samples from untreated patients with metastatic breast cancer. Conclusions: Our study provides a basis for the establishment of miRNAs as biomarkers for the detection and eventually staging of breast cancer through blood-borne testing. We identified and tested a set of putative biomarkers of breast cancer and demonstrated that altered levels of these miRNAs in serum from patients with breast cancer are particularly associated with the presence of metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605
A novel and universal method for microRNA RT-qPCR data normalization
Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009) · Genome Biology · doi:10.1186/gb-2009-10-6-r64 · Cited by 1,079
Duan, Z., Person, R. E., Lee, H.-H., Huang, S., Donadieu, J., Badolato, R., Grimes, H. L., Papayannopoulou, T., & Horwitz, M. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00762-07 · Cited by 91
Cited by
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K., & Schwarzenbach, H. (2014) · Oncotarget · doi:10.18632/oncotarget.2520 · Cited by 376
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 352
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
Cheng, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.001 · Cited by 334
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
McGuire, A., Brown, J. A. L., & Kerin, M. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9551-7 · Cited by 329
Metadata
- Authors
- van Schooneveld, E., Wouters, M. C., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J.
- Venue
- Breast Cancer Research
- Published
- 2012-02-21
- Volume
- 14
- Issue
- 1
- Pages
- R34-R34
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1993013702
- Cited by
- 191
- References
- 4
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. https://app.cochat.ai/papers/10.1186/bcr3127
- The paper
- van Schooneveld, E., Wouters, M. C., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2012). Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research. https://doi.org/10.1186/bcr3127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.